Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2001 2
2002 3
2004 1
2005 3
2006 1
2007 3
2008 2
2009 3
2010 2
2011 4
2012 1
2013 3
2014 2
2015 4
2016 4
2017 2
2018 5
2019 10
2020 8
2021 5
2022 13
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
S1-Leitlinie Atypisches Fibroxanthom (AFX) und pleomorphes dermales Sarkom (PDS).
Helbig D, Ziemer M, Dippel E, Erdmann M, Hillen U, Leiter U, Mentzel T, Osterhoff G, Ugurel S, Utikal J, von Bubnoff D, Weishaupt C, Grabbe S. Helbig D, et al. Among authors: weishaupt c. J Dtsch Dermatol Ges. 2022 Feb;20(2):235-245. doi: 10.1111/ddg.14700_g. J Dtsch Dermatol Ges. 2022. PMID: 35146874 German.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Schätzung der Prävalenz und Inzidenz von Hautkrebs in Deutschland.
Krensel M, Petersen J, Mohr P, Weishaupt C, Augustin J, Schäfer I. Krensel M, et al. Among authors: weishaupt c. J Dtsch Dermatol Ges. 2019 Dec;17(12):1239-1250. doi: 10.1111/ddg.14002_g. J Dtsch Dermatol Ges. 2019. PMID: 31885173 German.
S1-Leitlinie dermales und subkutanes Leiomyosarkom.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: weishaupt c. J Dtsch Dermatol Ges. 2023 May;21(5):555-564. doi: 10.1111/ddg.14989_g. J Dtsch Dermatol Ges. 2023. PMID: 37183752
S1-guideline cutaneous and subcutaneous leiomyosarcoma.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: weishaupt c. J Dtsch Dermatol Ges. 2023 May;21(5):555-563. doi: 10.1111/ddg.14989. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999582
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Franklin C, et al. Among authors: weishaupt c. J Immunother Cancer. 2023 Apr;11(4):e005828. doi: 10.1136/jitc-2022-005828. J Immunother Cancer. 2023. PMID: 37028819 Free PMC article.
Putative neuronal mechanisms of sensitive skin.
Ständer S, Schneider SW, Weishaupt C, Luger TA, Misery L. Ständer S, et al. Among authors: weishaupt c. Exp Dermatol. 2009 May;18(5):417-23. doi: 10.1111/j.1600-0625.2009.00861.x. Exp Dermatol. 2009. PMID: 19382311 Review.
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, Forschner A, Leiter U, Ulrich J, Utikal J, Welzel J, Kaatz M, Gebhardt C, Herbst R, Sindrilaru A, Dippel E, Sachse M, Meiss F, Heinzerling L, Haferkamp S, Weishaupt C, Löffler H, Kreft S, Griewank K, Livingstone E, Schadendorf D, Ugurel S, Zimmer L. Zaremba A, et al. Among authors: weishaupt c. Eur J Cancer. 2023 Jul;188:140-151. doi: 10.1016/j.ejca.2023.04.008. Epub 2023 Apr 24. Eur J Cancer. 2023. PMID: 37245442
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C. Schumann K, et al. Among authors: weishaupt c. J Eur Acad Dermatol Venereol. 2023 May;37(5):894-906. doi: 10.1111/jdv.18779. Epub 2022 Dec 12. J Eur Acad Dermatol Venereol. 2023. PMID: 36433688
80 results